Tagraxofusp - Stemline Therapeutics
Alternative Names: Diphtheria-toxin-interleukin-3-fusion-protein; DT(388)IL3; DT-388-IL-3; DT-IL-3; ELZONRIS; Elzonris; NS-401; SL-401; tagraxofusp-erzsLatest Information Update: 18 Jun 2024
At a glance
- Originator Scott & White Healthcare; Texas A&M University
- Developer Dana-Farber Cancer Institute; Nippon Shinyaku; Stemline Therapeutics
- Class Antineoplastics; Bacterial toxins; Immunotoxins; Interleukins; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Peptide elongation factor 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Blastic plasmacytoid dendritic cell neoplasm
- Phase II Acute myeloid leukaemia; Myeloproliferative disorders
- Phase I/II Multiple myeloma; Myelodysplastic syndromes
- No development reported Hairy cell leukaemia; Systemic scleroderma
Most Recent Events
- 18 Jun 2024 Stemline Therapeutics plans a phase II trial for Acute myeloid leukemia (Combination therapy, First line therapy) in USA (IV, Infusion) in August 2024 (EudraCT2024-514660-48-00) (NCT06456463)
- 01 May 2024 Phase-II clinical trials in Acute myeloid leukaemia (Combination therapy) in USA (IV) (NCT05442216)
- 13 Mar 2024 Stemline Therapeutics and Jonsson Comprehensive Cancer Center withdraws a phase-I trial in Acute myeloid leukaemia (Monotherapy, Combination therapy) prior to enrolment in the US (IV) (NCT05720988)